HC Wainwright reaffirmed their neutral rating on shares of Asensus Surgical (NYSEAMERICAN:ASXC - Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $0.35 price target on the stock.
Asensus Surgical Stock Up 1.8 %
ASXC stock traded up $0.00 during mid-day trading on Thursday, hitting $0.26. The stock had a trading volume of 787,624 shares, compared to its average volume of 1,440,314. Asensus Surgical has a 52 week low of $0.20 and a 52 week high of $0.65. The firm has a market cap of $71.21 million, a P/E ratio of -0.81 and a beta of 1.42.
Asensus Surgical (NYSEAMERICAN:ASXC - Get Free Report) last released its earnings results on Thursday, March 21st. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Asensus Surgical had a negative return on equity of 135.94% and a negative net margin of 914.46%. The business had revenue of $5.43 million for the quarter. Equities analysts predict that Asensus Surgical will post -0.19 EPS for the current year.
Institutional Investors Weigh In On Asensus Surgical
An institutional investor recently raised its position in Asensus Surgical stock. Avantax Planning Partners Inc. raised its position in shares of Asensus Surgical, Inc. (NYSEAMERICAN:ASXC - Free Report) by 773.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,936 shares of the company's stock after purchasing an additional 100,000 shares during the period. Avantax Planning Partners Inc.'s holdings in Asensus Surgical were worth $30,000 at the end of the most recent reporting period. 9.35% of the stock is currently owned by institutional investors.
Asensus Surgical Company Profile
(
Get Free Report)
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients.
Featured Articles
Before you consider Asensus Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Asensus Surgical wasn't on the list.
While Asensus Surgical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
